Cluster 3: benefit · risk · dose
Automatically detected text-similarity community. Keywords are calculated from article titles and summaries; membership is recalculated when the published corpus changes.
Is another dose comparison informative? A benefit–risk analysis of ifinatamab deruxtecan
Public randomized B7-H3 ADC dose-cohort counts used to quantify conditional information value, decision uncertainty and sensitivity to unreported joint outcomes and follow-up.
- From public randomized-cohort counts in IDeate-Lung01, 12 vs 8 mg/kg raised response by 27.4 points (95% credible interval +7.9 to +46.0), while the severe-adverse-event difference (+6.2, −14.0 to +26.3) remained uncertain.
- Another 50 participants per arm had an expected information value of 0.074 response-equivalent units per 100 future decision subjects at harm weight 1, rising to 1.62 and 11.02 at weights 2 and 4.
- Unreported joint response–harm outcomes and follow-up assumptions changed the value materially; patient-linked outcomes and an explicit preference definition may matter more than a larger repeat comparison.
How much of an existing drug's dose comparison can a new drug borrow?
Existing-drug dose comparisons inform priors for hypothetical new drugs. Under the defined utility and deterioration tolerance, weight 0.5 was acceptable in the main condition and 0.25 across all sensitivity conditions; these are not general borrowing rules.
- If the new drug matched the existing drug, borrowing the full dose comparison improved expected regret by only about 1 point and raised correct dose selection by 6 to 10 points.
- If the new drug favored the opposite dose, full borrowing lowered correct selection to 28 to 42% and worsened expected regret by 3.5 to 4.3 points.
- With 40 patients per arm the robust mixture prior hardly detected conflict; the largest weight that kept the loss within 1 point under every condition was 0.25 (0.5 in the main analysis).
RAS inhibitor dosing: from public PK/PD data to target-coverage scenarios
Public blood–tumor–DUSP6 reconstruction and hypothetical QD/BID comparisons with target turnover, variability and exposure costs.
- A public mouse blood–tumor–DUSP6 model was reconstructed and used to compare explicitly hypothetical QD, BID and TID regimens at the same normalized daily amount.
- In a reference virtual population, splitting the same daily amount raised the proportion keeping a concentration threshold for at least 90% of the interval from 20.6% to 61.5%; these are simulations, not response rates.
- Plasma half-life alone does not set dosing frequency: distribution, potency, target turnover and the lower tail of exposure decide where splitting matters, and these must be measured for a new RAS inhibitor.
How far does a dose-comparison trial support dose selection? Arm-level data for sotorasib 960 mg and 240 mg
Published arm-level data from a randomized dose comparison are used to show the decision regions as the weights on benefit and harm change. The difference in severe toxicity is robust, but differences in response rate and OS are uncertain, and the conclusion depends on how harm is defined. No clinical dose is recommended.
- Grade≥3 treatment-related adverse events were 16.0 points more frequent at 960 mg (95% interval +4.2 to +27.8), robust to the prior, data cutoff and correlation.
- The response-rate difference was +7.8 points (−4.3 to +19.8). Weighting one response and one severe toxicity about equally (w ≥ 0.95) favors 240 mg.
- The definition of harm moves the decision most, and the OS HR of 0.75 (0.53 to 1.07) leaves a signal favoring 960 mg. Arm-level public data alone cannot settle the dose.
From public T-cell engager evidence to the next experiment
Public PopPK and efficacy reconstruction, Bayesian CRS sensitivity, and hypothetical measurement value and sampling design.
- Using the published tarlatamab PopPK and Emax models in 5,000 virtual subjects, initial exposure matched label summaries, but steady-state troughs did not fully agree.
- Bayesian models of three aggregate CRS windows fitted the data, but the exposure-history timescale depended on the prior, so no optimal step-up among 14 schedules could be chosen.
- Matching dose intensity preserved average exposure but changed peaks and troughs, and early-only sampling did not stabilize CL; the framework specifies which measurements could change a decision, not a validated regimen.
What can aggregate randomized data establish about treatment duration and benefit–risk?
SCOT trial efficacy and neuropathy compared with endpoint-specific denominators, uncertainty, missingness bounds and limits of joint benefit–risk inference.
- From published SCOT results, 3 vs 6 months of adjuvant chemotherapy changed 3-year DFS by −0.4 points (−2.6 to +1.8), while grade ≥2 neuropathy fell by 33.4 points (26.9 to 39.5).
- Bounds that assign every missing neuropathy grade adversely still give a 27.6–36.6-point reduction within the safety cohort, so the toxicity benefit is robust to missing grades.
- Efficacy and toxicity come from different populations, so a joint 'disease-free without neuropathy' probability is not identified; non-inferiority is not the same as identical efficacy.